Fed cuts rates, will replace maturing bonds with T-bills amid data blackout and softening labor market.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Fed cuts rates, will replace maturing bonds with T-bills amid data blackout and softening labor market.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.